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Aims In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular
(CV) events by 15–16% in stable patients with a prior myocardial infarction (MI) 1–3 years earlier. We report the
efficacy and safety in the subpopulation recommended for treatment in the European (EU) label, i.e. treatment
with 60mg b.i.d. initiated up to 2 years from the MI, or within 1 year after stopping previous adenosine diphosphate
receptor inhibitor treatment.
...................................................................................................................................................................................................
Methods
and results
Of the 21 162 patients enrolled in PEGASUS-TIMI 54, 10 779 patients were included in the primary analysis for this
study, randomized to ticagrelor 60mg (n=5388) or matching placebo (n=5391). The cumulative proportions of patients
with events at 36months were calculated by the Kaplan–Meier (KM) method. The composite of CV death, MI, or stroke
occurred less frequently in the ticagrelor group (7.9% KM rate vs. 9.6%), hazard ratio (HR) 0.80 [95% confidence interval
(CI) 0.70–0.91; P=0.001]. Ticagrelor also reduced the risk of all-cause mortality, HR 0.80 (0.67–0.96; P=0.018).
Thrombolysis in myocardial infarction major bleeding was more frequent in the ticagrelor group 2.5% vs. 1.1%; HR 2.36
(1.65–3.39; P<0.001). The corresponding HR for fatal or intracranial bleeding was 1.17 (0.68–2.01; P=0.58).
...................................................................................................................................................................................................
Conclusion In PEGASUS-TIMI 54, treatment with ticagrelor 60mg as recommended in the EU label, was associated with a rela-
tive risk reduction of 20% in CV death, MI, or stroke. Thrombolysis in myocardial infarction major bleeding was
increased, but fatal or intracranial bleeding was similar to placebo. There appears to be a favourable benefit-risk
ratio for long-term ticagrelor 60mg in this population.
...................................................................................................................................................................................................
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Clinical trial
registration
http://www.clinicaltrials.gov NCT01225562
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Introduction
In acute coronary syndrome with or without ST-segment elevation,
European guidelines recommend dual antiplatelet treatment for at
least the first year.1,2 Notably, many stable patients with a history of
myocardial infarction (MI) remain at high risk after this period.3,4 In
PEGASUS-TIMI 54, ticagrelor, at doses of either 90mg b.i.d. or 60mg
b.i.d., significantly reduced the risk of the composite of major adverse
cardiovascular events [MACE; cardiovascular (CV) death, MI, or
stroke] by 15–16% in stable patients at high risk with a prior MI
1–3 years earlier.5 The benefit of ticagrelor appeared more marked in
patients continuing on or restarting after only a brief interruption of
adenosine diphosphate (ADP) receptor inhibition and in those closer
to their qualifying MI.6 Accordingly, the CHMP-EMA approved
European (EU) label recommends that, after the initial 1-year treat-
ment with ticagrelor 90mg b.i.d. (or other ADP receptor inhibitor) in
high-risk MI patients, treatment with ticagrelor 60mg b.i.d. may be
started without interruption as continuation therapy.7 Treatment
with ticagrelor 60mg b.i.d. can also be initiated up to 2 years from the
MI, or within 1 year after stopping previous ADP receptor inhibitor
treatment. While the PEGASUS-TIMI 54 trial had wider inclusion cri-
teria, the present analysis aimed to describe the effects of extended
treatment with ticagrelor 60mg b.i.d. in a clinically relevant subset of
patients, treated according to the approved label. We, therefore, re-
port the efficacy and safety in the PEGASUS-TIMI 54 subpopulation
recommended for treatment in the EU label.
Methods
Study population
PEGASUS-TIMI 54 randomized patients with prior MI to ticagrelor 60mg
b.i.d., ticagrelor 90mg b.i.d., or placebo, all on a background of low-dose
aspirin. The protocol was approved by the relevant ethics committee at
each participating site. Written informed consent was obtained from all
the patients. The design8 and primary results of the trial have been pub-
lished.5 In brief, patients aged at least 50 years were included with a spon-
taneous MI occurring 1–3 years prior to enrolment and at least one of
the following additional high-risk features: age of 65 years or older, dia-
betes mellitus requiring medication, a second prior spontaneous MI, mul-
tivessel coronary artery disease, or chronic renal dysfunction, defined as a
creatinine clearance <60mL/min as estimated by the Cockroft–Gault
equation. Patients were ineligible if there was planned use of a P2Y12 re-
ceptor antagonist or anticoagulant therapy during the study period; if
they had a bleeding disorder, a history of intracranial bleeding, a central
nervous system tumour, or an intracranial vascular abnormality; or if they
had had gastrointestinal bleeding within the previous 6months or major
surgery within the previous month.
The present analysis focuses on data from 10 779 patients that
were randomized <_2 years from qualifying MI or <_1year from prior
stopping ADP receptor inhibitor treatment, 5388 in the ticagrelor
60mg and 5391 in the placebo group (EU label group). Patients
randomized to ticagrelor 60mg or placebo who did not qualify per
the EU label are termed the non-EU label group. Data on patients
randomized to ticagrelor 90mg who would have qualified for the EU
label (n=5374) are also presented in the Supplementary material
online for the sake of completeness.
Endpoints
The primary efficacy endpoint for PEGASUS-TIMI 54 was the composite
of CV death, MI, or stroke (MACE). Additional efficacy endpoints
included the individual components of the composite as well as coronary
heart disease-related death and all-cause mortality. The primary safety
endpoint was Thrombolysis in myocardial infarction (TIMI) major bleed-
ing. Other safety endpoints included TIMI minor bleeding, intracranial
haemorrhage, and fatal bleeding. All potential events were adjudicated by
the TIMI clinical events committee, which was blinded to treatment allo-
cation. Net clinical benefit was calculated as the number of events pre-
vented (CV death, MI, stroke, or the composite of these) vs. events
caused (TIMI major bleeding, intracranial haemorrhage, or fatal bleeding)
per 1000 patients treated for 3 years with ticagrelor. Within these events
we also examined the irreversible hard outcomes which included all of
the aforementioned outcomes except TIMI major bleeding.9
Statistical considerations
Cumulative event rates at 3 years were calculated by the complement
of the Kaplan–Meier (KM) survival estimates. Hazard ratios (HRs) and
95% confidence intervals (CIs) were generated with the use of a Cox
proportional-hazards model, and all reported P-values are two-sided.
Interactions between the agreed EU label and the treatment group
were also examined by Cox proportional hazards model. The as-
sumption of proportional hazards was tested by including time de-
pendent covariates in the model and examined by scaled Schoenfeld
residual plots. Number needed to treat (NNT) was calculated by the
reciprocal of the absolute risk difference based on 3 year KM esti-
mates. The number of events prevented and caused per 1000 patients
were based on the difference between 3 years incidence rates/person
years in the treatment and placebo arm, with negative difference
being ‘prevented’ events and positive difference being events ‘caused’
by treatment arm. This difference was multiplied by 1000 to aid the
clinical interpretation. Efficacy analyses were performed on an
intention-to-treat basis. Safety analyses included all the patients who
received at least one dose of study drug and included all the events
occurring after receipt of the first dose and within 7 days of the last
dose of study drug. The bleeding analysis is on-treatment. Results for
the 90mg b.i.d. dose are presented in the Supplementary material
online.
All analyses were performed according to the intention-to-treat prin-
ciple, utilizing SAS version 9.4. The statistical significance was set at an
a-level of 0.05 significance.
Results
A total of 14 112 patients were randomized to ticagrelor 60mg bid
(the EU dose approved for long-term therapy) or placebo. Of this
The EU perspective: ticagrelor in patients with prior MI 201
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group, 10 799 patients were within 2 years from qualifying MI or with-
in 1 year from prior ADP receptor inhibitor treatment and were
randomized to ticagrelor 60mg bid or placebo. As expected, there
were no differences in baseline characteristics by randomized treat-
ment arm (Table 1). An additional 3333 patients were in the ticagre-
lor 60mg or placebo arms but fell outside the EU label parameters.
The median time from MI was 1.5 years vs. 2.5 years and median time
from P2Y12-treatment discontinuation was 34days vs. 588 days for
the EU label vs. non-EU label patients, respectively. Compared with
non-EU label patients, EU label patients were more likely to have had
a history of multivessel coronary artery disease (61.4% vs. 53.7%,
P<0.001) and a history of percutaneous coronary intervention
(PCI) (84.9% vs. 77.1%, P<0.001) (Supplementary material online,
Table S1).
In addition, there were 5374 patients randomized to ticagrelor
90mg within 2 years from qualifying MI or within 1 year from prior
ADP receptor inhibitor treatment (see Supplementary material on-
line, Table S2).
Efficacy
In the EU label population, the composite of CV death, MI, or stroke
occurred in 373 patients (KM rate 7.9%) in the ticagrelor 60mg group
and in 463 patients in the placebo group (KM rate 9.6%; Figure 1); HR
0.80 (95% CI 0.70–0.91; P=0.001), when compared with HR 1.00
(95% CI 0.77–1.30; P=0.98) among the non-EU label population
(P-value for interaction 0.12). The absolute risk reduction over
3 years was 1.7%, leading to a NNT of 58. In the EU label population,
corresponding HRs for the components of the primary composite
endpoint were 0.71 (95% CI 0.56–0.90; P=0.0041) for CV death,
0.83 (95% CI 0.70–0.99; P=0.041) for MI, and 0.74 (95% CI 0.55–
1.01; P=0.058) for stroke (Table 2). The HR for coronary heart dis-
ease death was 0.72 (95% CI 0.53–0.97; P=0.03) and for all-cause
death 0.80 (95% CI 0.67–0.96; P=0.018) (see Figure 2).
The efficacy results were virtually identical when comparing
patients who would qualify for the EU label but were randomized to
ticagrelor 90mg to placebo, with a HR for CV death, MI, or stroke of
0.80 (95% CI 0.70–0.92; P=0.0015) (Supplementary material online,
Table S3). We also did a further subgroup analysis examining the effi-
cacy of ticagrelor in patients with just one or both of the EMA
requirements (MI within 2 years and within 1 year from stopping pre-
vious P2Y12 receptor inhibitor). Among patients who qualified on
both points, the benefit of ticagrelor was most apparent
(Supplementary material online, Table S4). In patients who qualified
on just one of the EMA requirements, the difference between tica-
grelor and placebo did not reach statistical significance although the
trend towards the benefit is still present.
......................................................................... .........................................................................
....................................................................................................................................................................................................................
Table 1 Baseline characteristics ticagrelor 60mg and placebo, European label and non-European label population
Characteristics EU label population Non-EU label population
Ticagrelor 60mg bid
(N5 5388)
Placebo (N5 5391) Ticagrelor 60mg bid
(N51657)
Placebo (N5 1676)
Age (years), mean (SD) 65.1 (8.5) 65.3 (8.3) 65.5 (8.1) 65.6 (8.2)
Female 1267 (23.52%) 1314 (24.37%) 394 (23.78%) 403 (24.05%)
White 4592 (85.23%) 4606 (85.44%) 1485 (89.62%) 1518 (90.57%)
Weight, mean (SD) 81.9 (17.1) 81.6 (16.8) 82.5 (16.6) 82.5 (16.0)
History of hypertension 4183 (77.65%) 4175 (77.44%) 1278 (77.13%) 1309 (78.1%)
History of hypercholesterolaemia 4122 (76.52%) 4179 (77.52%) 1258 (75.97%) 1272 (75.94%)
Current smoker 939 (17.43%) 865 (16.06%) 267 (16.11%) 278 (16.59%)
History of diabetes 1774 (32.93%) 1710 (31.72%) 534 (32.25%) 547 (32.64%)
Multivessel coronary artery disease 3313 (61.5%) 3300 (61.21%) 877 (52.99%) 913 (54.47%)
History of PCI 4584 (85.09%) 4563 (84.66%) 1295 (78.15%) 1274 (76.01%)
History of second prior MI 884 (16.41%) 900 (16.69%) 284 (17.15%) 288 (17.18%)
History of PAD 301 (5.59%) 317 (5.88%) 67 (4.04%) 87 (5.19%)
eGRR <60 mL/min/1.73 m2 1178 (22.16%) 1239 (23.25%) 369 (22.51%) 410 (24.77%)
Qualifying event
Years since MI, median (IQR) 1.5 (1.2–1.9) 1.5 (1.2–1.9) 2.5 (2.3–2.8) 2.5 (2.3–2.8)
Type of MI
NSTEMI 2209 (41.04%) 2177 (40.43%) 633 (38.32%) 666 (39.81%)
STEMI 2872 (53.35%) 2928 (54.38%) 885 (53.57%) 881 (52.66%)
Unknown 302 (5.61%) 279 (5.18%) 134 (8.11%) 126 (7.53%)
Medications at baseline
Aspirin 5381 (99.87%) 5382 (99.83%) 1655 (99.88%) 1675 (99.94%)
Statin 4999 (92.78%) 5049 (93.66%) 1496 (90.28%) 1534 (91.53%)
Beta blocker 4462 (82.81%) 4518 (83.81%) 1334 (80.51%) 1360 (81.15%)
ACE-I or ARB 4310 (79.99%) 4341 (80.52%) 1321 (79.72%) 1356 (80.91%)
There were no statistically significant differences in baseline characteristics by treatment arm within the EU and non-EU label subgroups.
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Safety
Thrombolysis in myocardial infarction major bleeding occurred in 94
patients (KM rate 2.5%) in the ticagrelor 60mg group and in 43
patients (KM rate 1.1%) in the placebo group; number needed to
harm 76, HR 2.36 (1.65–3.39, P<0.001; Table 3), when compared
with HR 2.13 (95% CI 1.03–4.43; P=0.04) among non-EU label
patients (P-value for interaction 0.81). The corresponding HRs for
fatal or intracranial bleeding were 1.17 (0.68–2.01; P=0.58) in the EU
label subgroup, when compared with HR 1.36 (95% CI 0.41–4.46;
P=0.61) among the non-EU label patients. The HR for major bleed-
ing for patients who would qualify for the EU label but were random-
ized to ticagrelor 90mg vs. placebo was 2.59 (95% CI 1.81–3.70)
(Supplementary material online, Table S5).
Net clinical benefit
The number of events prevented and caused per 1000 patients is
shown in Figure 3. Treating 1000 patients with ticagrelor 60mg b.i.d.
for 3 years would be expected to prevent 24 major adverse CV
events, including 10 CV deaths, 9 MIs, and 5 strokes, while causing
10 major bleeds but no cases of intracranial or fatal bleeding.
Thus, the NNT over 3 years to prevent one irreversible event
(CV death, MI, stroke, intracranial haemorrhage, or fatal bleed-
ing) was 42.
Discussion
The present analysis defines the clinical efficacy of dual antiplatelet
treatment with 60mg b.i.d. ticagrelor post-MI when initiated
according to the CHMP-EMA approved EU label, i.e. that after the
initial year of treatment with 90mg ticagrelor b.i.d., the patient is
shifted to 60mg b.i.d. without, or with only a briefer interruption.7
In such a population, ticagrelor reduced the risk of the primary
endpoint of CV death, MI, or stroke by 20%, coronary heart death
by 28%, CV mortality by 29%, and all-cause mortality by 20%.
Figure 1 Primary endpoint for ticagrelor 60mg vs. placebo, European label and non-European label patients. T60 EU: ticagrelor 60mg according
to European label. Placebo EU: placebo treatment according to European label. T60 N-EU: ticagrelor 60mg to non-European label patients. Placebo
N-EU: placebo treatment to non-European label patients.
....................................................... ......................................................
....................................................................................................................................................................................................................
Table 2 Efficacy of ticagrelor 60mg vs. placebo in the European label population
Outcomes Ticagrelor 60mg bid (N5 5388) Placebo (N5 5391) HR (95% CI) P-value
Number of events KM rate (%) Number of events KM rate (%)
Composite of CV death/MI/Stroke 373 7.85 463 9.56 0.80 (0.70–0.91) 0.0011
CV death 119 2.58 167 3.58 0.71 (0.56–0.90) 0.0041
Coronary heart disease death 75 1.59 104 2.15 0.72 (0.53–0.97) 0.0282
MI 230 4.85 274 5.59 0.83 (0.70–0.99) 0.0406
Stroke 71 1.52 95 2.04 0.74 (0.55–1.01) 0.0583
All-cause mortality 206 4.44 256 5.39 0.80 (0.67–0.96) 0.0183
The EU perspective: ticagrelor in patients with prior MI 203
..................................................... ....................................................
....................................................................................................................................................................................................................
Table 3 Safety of ticagrelor 60mg vs. placebo in the European label population
Outcomes Ticagrelor 60mg bid (N5 5322) Placebo (N5 5331) HR (95% CI) P-value
Number of events KM rate (%) Number of events KM rate (%)
TIMI major bleeding 94 2.46 43 1.14 2.36 (1.65–3.39) <0.0001
TIMI minor bleeding 49 1.39 15 0.39 3.50 (1.96–6.25) <0.0001
Fatal bleeding 9 0.29 11 0.33 0.88 (0.37–2.13) 0.7825
Intracranial haemorrhage 23 0.68 18 0.49 1.38 (0.74–2.55) 0.3085
Fatal bleeding or intracranial haemorrhage 27 0.79 25 0.67 1.17 (0.68–2.01) 0.5777
Figure 2 All-cause death for ticagrelor 60mg vs. placebo, European label and non-European label patients. T60 EU: ticagrelor 60mg according to
European label. Placebo EU: placebo treatment according to European label. T60 N-EU: ticagrelor 60mg to non-European label patients. Placebo
N-EU: placebo treatment to non-European label patients.
Figure 3 Clinical events prevented and caused per 1000 patients initiated on ticagrelor 60mg b.i.d. and followed for 3 years.
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Various mechanisms may explain the apparently enhanced bene-
fit of ticagrelor in this population: for example, there is an
increased MACE rate in the first 3 months after cessation of
P2Y12 receptor inhibitor
6,10 so ticagrelor-treated patients in the
EU label group would have received some protection during this
higher-risk period. Furthermore, there was a higher proportion
of patients with multivessel coronary artery disease in the EU
label group and we have shown these patients to have a greater
absolute risk reduction with ticagrelor, including for coronary
heart disease-related death, compared to patients with single-
vessel disease.11 Our analysis aims to guide prescribing clinicians
by aiding prediction of the benefit that might be achieved when
patients meeting the EU label criteria are switched to ticagrelor
60mg b.i.d. after 1 year of treatment with ticagrelor 90mg b.i.d.
The US label for ticagrelor is different from the EU label in that it
suggests down-shifting from 90 to 60mg b.i.d. after 12 months of
treatment but otherwise has no suggested time limits or time-
based guidance.
Any consideration of prolonged antithrombotic therapy must also
take safety into account. As expected, prolonged antithrombotic
therapy was associated with more bleeding, but fatal or intracranial
bleeding was not increased in this population in whom a high risk of
life-threatening bleeding had been excluded at enrolment. Thus, in
terms of net clinical benefit, for every 1000 eligible patients treated
for 3 years, 24 major CV events would be avoided at the cost of only
10 major bleeds. Moreover, there was no excess of fatal or intracra-
nial bleeds, and all-cause mortality was reduced.
Decisions on the safety and effectiveness of a drug in its
intended use can be guided by an evaluation of the balance be-
tween the benefits and risks. The appropriate approach to such
evaluation needs to depend on the severity of the disease and the
intervention studied. The full complement of efficacy outcomes
and safety evaluations in PEGASUS encompasses a range of event
types with varying clinical significance; however, the assessment of
the benefit-risk profile of ticagrelor used focuses primarily on
those events with the greatest clinical importance. This approach
has been supported as the most appropriate one for the assess-
ment of benefit-risk balance since it compares endpoints of similar
clinical impact, and integrates clinical judgement supported by
quantitative analysis.9
While other therapeutic options may be considered such as the
combination of low-dose factor Xa treatment12 and aspirin that com-
bination has only been reported on patients further away from their
index infarction. There are no directly comparative studies between
long-term dual antiplatelet treatment with ticagrelor or treatment
with low-dose factor Xa inhibitors on top of aspirin.
Limitations
This is, by definition, a post hoc analysis since this subset was defined
by regulators and not prospectively. The statistical analysis did not ac-
count for multiplicity of testing and this was not a prespecified ana-
lysis so therefore per se is hypothesis generating. However, the
present analysis is of major clinical relevance to physicians and
patients since this defines the benefits and risks to be expected in
routine clinical practice.
Conclusions
In PEGASUS-TIMI 54, treatment with ticagrelor 60mg b.i.d. in
patients more recent to their MI or ADP receptor blocker discon-
tinuation, as recommended in the EU label, reduced the risk of CV
death, MI, or stroke by 20%, CV death by 29%, and all-cause mortality
by 20%. Overall TIMI major bleeding was increased, but fatal or intra-
cranial bleeding were not significantly different from placebo. There
appears to be a favourable benefit-risk balance for long-term ticagre-
lor 60mg b.i.d. in this population.
Supplementary material
Supplementary material is available at European Heart Journal –
Cardiovascular Pharmacotherapy online.
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